Alcon (ALC) announced its intention to acquire LumiThera and its PBM device for the treatment of early and intermediate dry AMD. LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living with early to intermediate dry AMD. The transaction does not include the acquisition of AdaptDx and Nova/Diopsys diagnostic devices, which will be separated and spun-off to LumiThera’s shareholders prior to Alcon’s acquisition and will continue to be marketed and sold by the LumiThera spin-off. Subject to customary closing conditions and a LumiThera shareholder vote, Alcon and LumiThera anticipate the acquisition to be completed in the third quarter of 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALC:
- Alcon price target raised to CHF 101 from CHF 99 at Citi
- Alcon’s Stock Boosted by FDA Approval of Innovative Dry Eye Drug TRYPTYR
- Alcon’s Strategic Initiatives and Valuation Justify Buy Rating with $99 Price Target
- Alcon Secures FDA Approval for TRYPTYR to Treat Dry Eye Disease
- Alcon’s Tryptyr approved by FDA for signs and symptoms of Dry Eye Disease